COVID-19 Impacts and Recovery | Global Fire Detection And Suppression Systems Market Research during 2020-2024

Business Wire
Frontdoor to Participate at the Truist Securities Technology, Internet & Services Conference
Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, today announced it is attending the Truist Securities Technology, Internet & Services Conference, and that management will participate in a fireside chat to be held virtually on March 9, 2021.
a minute ago
Reuters
Explainer: Why protests are shaking one of Africa's most stable democracies
Clashes between police and thousands of demonstrators protesting at the detention of Senegal's most prominent opposition leader have killed at least five people since last week. Ousmane Sonko was indicted and released on bail under judicial supervision on Monday but an opposition coalition has called for three days of protests from Monday. The unrest is the worst in a decade in Senegal, widely seen as one of West Africa's most stable democracies.
2 minutes ago
Motley Fool
What Stock Market Sell-Off? These Stocks Are Red Hot
While a major index recently entered correction territory, one group of stocks has continued surging.
3 minutes ago
Business Wire
Glenfarne Group and Partners Group Announce EnfraGen’s Expanded Presence in Colombia Through Termovalle Acquisition
EnfraGen, LLC ("EnfraGen"), a developer, owner, and operator of grid stability and value-added renewable power and assets in Latin America, jointly owned by Glenfarne Group and Partners Group, on behalf of its clients, announced today the close of its acquisition of Termovalle S.A.S. E.S.P., the largest natural gas-fired plant in Western Colombia. The sellers are Juneau Business Inc., Termovalle Investment Limited, Altra Private Equity Fund II LP, Altra Private Equity Fund II-A, Fondo de Capital Privado Altra FCP II and Altra Investments II GP Inc. With an installed capacity of 241 MW, the acquisition brings EnfraGen’s portfolio of operating and in-construction power assets to a combined capacity of approximately 1.7 GW. Following the acquisition, Termovalle will be renamed Prime Termovalle S.A.S. E.S.P.
3 minutes ago
Business Wire
Global Greeting Cards Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com
The "Greeting Cards - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
3 minutes ago
Reuters
Saudi wealth fund PIF to support corporate credit growth, S&P says
Investments by Saudi Arabia's wealth fund Public Investment Fund (PIF) will support credit growth among companies in the kingdom, ratings agency S&P Global Ratings said on Monday. "The Public Investment Fund has recently announced investment initiatives that we expect will spur corporate credit growth, mostly in construction-related industries," S&P said. Domestic credit growth in Saudi Arabia, the biggest Arab economy, is expected to stay strong this and next year after a 14% year-on-year increase in 2020, S&P said.
4 minutes ago
GlobeNewswire
Consolidated Water to Participate at the Virtual 33rd Annual ROTH Conference on March 15-17, 2021
GEORGE TOWN, Cayman Islands, March 08, 2021 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees that include institutional investors, analysts, family offices and high-net-worth investors. Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with investors and analysts during the conference. He will be joined by the company’s CFO, David Sasnett. Management will discuss matters of interest to investors, including the company’s performance through the ongoing COVID-19 pandemic and growth opportunities in its recently acquired subsidiary, PERC Water Corporation located in Southern California. To submit a registration request, click here. To schedule a one-on-one meeting with Consolidated Water, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com. About Consolidated Water Co. Ltd.Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The company operates water production facilities in the Cayman Islands, The Bahamas and the British Virgin Islands and operates water treatment facilities in the United States. The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment. For more information, visit www.cwco.com. Company Contact:David W. SasnettExecutive Vice President and CFOTel (954) 509-8200dsasnett@cwco.com Investor Relations ContactRon Both, CMATel (949) 432-7566CWCO@cma.team
5 minutes ago
GlobeNewswire
OSS to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
ESCONDIDO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, has been invited to participate at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees, including institutional investors, analysts, family offices and high-net-worth investors. OSS president and CEO, David Raun, will participate in one-on-one meetings with investors and analysts during the conference. He will be joined by the company’s CFO, John Morrison, and chief sales and marketing officer, Jim Ison. To submit a registration request, click here. To schedule a one-on-one meeting with OSS, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com. About One Stop SystemsOne Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance computing modules and systems, including customized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator storage software. These products are used for deep learning, AI, defense, finance and entertainment applications, and empower scientists, engineers, creators and other professionals to push the boundaries of their industries. OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge’ and on mobile platforms, and by addressing the entire AI workflow, from high speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. Forward-Looking StatementsOne Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including, without limitation: risks associated with the fitness of One Stop Systems products and applications in certain industries; risks associated with the performance of our products that are combined into a third party's product, system, or application; and other risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Media Contact:Katie RiveraOne Stop Systems, Inc.Tel (760) 745-9883Email contact Investor Relations:Ronald Both or Grant StudeCMATel (949) 432-7557Email contact
5 minutes ago
GlobeNewswire
Keith Cochran Joins KULR Technology Group as President & COO
Former Jabil SVP of $3.7 billion Asian smartphone division to lead growth initiatives in large-scale manufacturing automation and operational expansion SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- KULR Technology Group Inc. (OTCQB: KULR) (the "Company" or "KULR"), a leading developer of next-generation lithium-ion battery safety and thermal management technologies, today announces veteran manufacturing and operations executive Keith Cochran has joined the Company as President and Chief Operating Officer. An accomplished senior-level executive, Cochran brings over 25 years of successful operations and business management experience to KULR Technology Group. Prior to KULR, Mr. Cochran was most recently Senior Vice President of Jabil Greenpoint's (NYSE: JBL) Global Business Units in Singapore, where he led the $3.7 billion revenue smartphone technology division. Under his management, he oversaw a team employing over 65,000 people in the United States and Asia, managed over 45 original equipment manufacturers simultaneously, served as Country Manager in India and Brazil, and was the recipient of multiple Supplier of the Year awards. As KULR Chief Operating Officer, Mr. Cochran will provide the leadership and organizational experience necessary to ensure KULR has proper operational controls and procedures in place to effectively manufacture and automate on mass scale with sound operating efficiency. Cochran brings a combination of international manufacturing experience, operations improvement and global go-to-market expertise to the California based thermal management company. Having driven growth strategies globally within several business units at Jabil, Inc., he will also focus on potential operational synergies inside Europe and Asia. “As someone who has a passion for people and motivating others, as well as a love for industrial engineering and product manufacturing, I couldn’t imagine a better place to continue my career than at KULR Technology Group,” said Cochran. “I look forward to building a strong and successful operations unit that will help KULR deliver its carbon fiber thermal management technologies to the masses.” "Keith has a broad 25-year supply chain management background, and in his tenure at Jabil he demonstrated an astute ability to run day-to-day operations on a large scale while executing difficult changes with exceptional results," said Michael Mo, KULR Technology Group CEO. "He is an outstanding addition to our team and we value his guidance as he leads KULR's operational expansion going forward." As a senior member of the leadership team, Cochran will report directly to KULR CEO, Michael Mo. About KULR Technology Group Inc. KULR Technology Group Inc. (OTCQB:KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Leveraging the company's roots in developing breakthrough cooling solutions for NASA space missions and backed by a strong intellectual property portfolio, KULR enables leading aerospace, electronics, energy storage, 5G infrastructure, and electric vehicle manufacturers to make their products cooler, lighter and safer for the consumer. For more information, please visit www.KULRTechnology.com. Safe Harbor Statement This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on May 14, 2020. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. Media Contact: Derek Newton Head, Media Relations Main: (786) 499-8998 Derek.Newton@KULRTechnology.com Investor Relations: KULR Technology Group Inc. Main: (888) 367-5559 IR@KULRTechnology.com
6 minutes ago
GlobeNewswire
Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management System
MINNEAPOLIS, March 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its Skyline Medical Division is renewing developing a new Generation 3 STREAMWAY ® System for direct-to-drain fluid waste management. The new device will see no change to its intended use and will not require a separate 501(k) submission with the Food and Drug Administration. Some of the key changes to the new generation product will include a 25% size reduction, a portable wall mounting plate to simplify installation thus reducing installation costs, an automated dripless system that ensures optimal reliability when changing out the filters between procedures, modularized subassemblies which will streamline assembly and servicing, a new drop down cover design that allows for access to the core of the unit also for easier servicing, a new software providing state of the art on screen graphics with the latest technology to allow for on screen training as needed, a reduction in both electrical and mechanical internal connections increasing vacuum efficiency, eliminating relays and I/O’s (input/output) through a newly developed integrated PC board providing for real time fluid waste measurement. Lastly, this new design will be smaller, lighter, easier to install with the goal of improving operator reliability, reducing manufacturing costs, increasing durability and simplifying servicing. “Skyline Medical plans to follow shortly with a Generation 3 Plus machine which includes an integrated on board vacuum pump so the facility vacuum supply will not be required or at the least can be augmented if needed,” commented Dr. Carl Schwartz, CEO of Predictive Oncology. About Predictive Oncology Inc. Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. Forward-Looking Statements Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements. Investor Relations Contact: Landon Capital Keith Pinder (404) 995-6671kpinder@landoncapital.net
6 minutes ago
Business Wire
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories to present at Barclays Global Healthcare Conference
6 minutes ago
Business Wire
Danimer Scientific Announces Date for Fourth Quarter and Full Year 2020 Results
Danimer Scientific (NYSE: DNMR) ("Danimer" or the "Company"), a leading developer and manufacturer of biodegradable materials, announced today that the Company will release its fourth quarter and full year 2020 financial results after the market closes on Monday, March 29, 2021. A webcast and conference call will be held that same day at 5:00 p.m. Eastern Time to review the Company’s fourth quarter and full year results, discuss recent events and conduct a question-and-answer session.
6 minutes ago
GlobeNewswire
Fieldpoint Private Surpasses Two Major Milestones
Firm Tops $1 Billion in Bank Assets, $5 Billion in Investment AssetsGREENWICH, Conn., March 08, 2021 (GLOBE NEWSWIRE) -- Fieldpoint Private, the fast-growing wealth advisory and private banking boutique serving families and institutions, announced it has surpassed the $1 billion threshold in total bank assets, and $5 billion in total wealth management assets. The 12-year-old firm now ranks within the top 20 percent of U.S. banks by assets, and was recently named among America’s top 100 independent investment firms by Barron’s magazine. Since its 2008 founding in Greenwich, Connecticut, Fieldpoint Private has grown its presence to include New York City, Georgia and Florida, earning the business of families, entrepreneurs, businesses and charitable institutions in 46 states. It has attracted leadership, advisors and bankers from Bank of America, BNY Mellon, Brown Brothers Harriman, Citigroup, Goldman Sachs, J.P. Morgan, Morgan Stanley, Merrill Lynch, Neuberger Berman, Wells Fargo and others, as well as deeply rooted community banks. Chairman and CEO Tim Tully said that while it is important to take a moment to recognize these milestones, growth - by itself - was never the firm’s mandate. “Our goal has always been to create a new standard of service for clients, to maintain independence of thought and protect our commitment to do what’s right for the client, wherever that takes us.” He added, “It’s clearly taking us to a pretty good place, and I’m grateful to our colleagues for all they have done to get us here, and to our clients for their trust and enthusiasm along the way.” Russell Holland, President and CEO of Fieldpoint Private’s banking unit, said that when Fieldpoint was founded, clients could get commercial and personal banking, along with investment advice at any number of the giant global firms. “But clients felt the advice and experience was disconnected and too often met the interests of the firm more than themselves and their families,” he said. Christopher DeLaura, President and CEO of the firm’s wealth management unit added, “Delivering all of this, in a boutique experience, with fully integrated advice and world-class intellectual capital, was something no one had tried before. These milestones tell us it was an important idea at the right time, and we feel like we are just getting started.” About Fieldpoint PrivateHeadquartered in Greenwich, Connecticut, Fieldpoint Private (www.fieldpointprivate.com) is a boutique financial firm providing the highest degree of personalized, confidential wealth planning and private banking services. Catering to highly successful individuals, families, businesses and institutions, Fieldpoint Private offers a powerful combination of wealth management and strategy, family office, private banking and business banking services addressing every financial need for each of our clients including: wealth transfer advice, tax planning, aggregation and performance reporting, risk management, goals-based investing strategies, sophisticated investment selection, discreet and personalized banking, highly customized credit solutions, custom custody and trust solutions, highly attentive and responsive service, and concierge services. Fieldpoint Private was established in 2008 by 31 Founders with a specific vision and purpose. These extraordinary leaders of industry and community recognized the opportunity to create a financial firm totally attuned to people’s individual circumstances. Our firm is built on a philosophy of exclusive membership and client-centricity. Working with a limited number of relationships gives every person the experience of belonging to an extremely selective group. The result is a new breed of institution established on the basis of personalization, responsiveness, and exclusivity, and an ensured commitment to impeccable service and consistently flawless execution. Our service approach offers a unique client experience custom crafted to each client’s financial needs. Banking Services: Fieldpoint Private Bank & TrustRegistered Investment Advisors: Fieldpoint Private Securities, LLC, is a SEC Registered Investment Advisor and Broker Dealer. Member FINRA, MSRB, SIPC. CONTACT: Media Contact: Michael White Chief Marketing Officer Fieldpoint Private 203.413.9340 mwhite@fieldpointprivate.com
6 minutes ago
GlobeNewswire
LMN Architects and Booth Hansen Celebrate the Design and Construction of the New Computer Design, Research, and Learning Center at the University of Illinois Chicago
The Computer Design Center will be a new campus hub and is being delivered on an accelerated schedule to meet the demands of the department, doubling its capacity by 2023. Exterior view of the new Computer Design, Research, and Learning Center at UIC. Located at a unique, prominent site on campus, the structure celebrates the natural setting and organic form of the Memorial Grove and establishes a new front door for technology in Chicago. Rendering: © LMN Architects. Interior view of the new Computer Design, Research, and Learning Center at UIC. Together with the existing lab building, the new CDRLC creates a dramatic public atrium for social interactions with visual and physical connections to all floors. Rendering: © LMN Architects. Seattle, March 08, 2021 (GLOBE NEWSWIRE) -- LMN Architects in collaboration with Booth Hansen is pleased to celebrate the design and construction of the new Computer Design, Research, and Learning Center at the University of Illinois in Chicago. Located at a unique prominent site on campus, the structure celebrates the garden and elliptical form of the Harry W. Pearce Memorial Grove and establishes a new front door for technology in downtown Chicago. The University of Illinois Chicago (UIC) is Chicago’s only public research university and one of the most diverse universities in the United States. The new 135,000 SFT Computer Design, Research, and Learning Center (CDRLC) at UIC will consolidate the currently fragmented Computer & Science Department in a new home and co-locate it with a large cluster of university-administered classrooms at the heart of the east campus. The building is designed to be a welcoming, inclusive, and inviting space for the diverse student body. The building will serve research needs with state-of-the-art facilities, accommodate the rapidly increasing undergraduate enrollment in computer science and become a new campus hub. "Illinois is home to the best universities and research centers in the world and boasts a talented workforce that attracts companies from across the globe," said Governor JB Pritzker. "This new learning center on the UIC campus, made possible through funding from our historic bipartisan Rebuild Illinois capital plan, will further cement the university's place as a world-class institution that excels in preparing talented students for the careers of tomorrow." “This project is a top priority to meet the needs of students in our growing computer science program and helps to strengthen the high-tech boom in Chicago. We are grateful to Governor Pritzker for his support,” said UIC Chancellor Michael D. Amiridis. “The new CDRLC represents the future of higher education at UIC and is intended to be a welcoming space to promote innovation, collaboration, and discovery. We placed an intentional emphasis on the public spaces, research labs and collaborative areas to enhance the experience that each student will have, and it has been a pleasure collaborating with LMN Architects and Booth Hansen,” said Peter Nelson, Dean, UIC College of Engineering. “Students at UIC will have a new building on campus where they can unleash their curiosity and enjoy a space that is focused on learning, research and teamwork.” The CDRLC is the third recent academic building to be built on the east campus originally designed by Walter Netsch in 1965. The building will be delivered on an accelerated schedule to meet the demands of the department, doubling its capacity by 2023. It will create a hub for both engineering and computer science that includes research areas comprised of faculty offices, collaboration areas, dry lab and specialty lab; administrative and student affairs office spaces; collaborative teaching and learning spaces for undergraduate and graduate students; an undergraduate learning and community center; and a flexible events room; all stitched together by a five-story daylit atrium. “Together with the department, University, and CBD, our team of LMN and Booth Hansen have designed the building to become a welcoming hub, a building that embraces the old and presents an iconic new presence along Taylor Street,” says LMN Partner Stephen Van Dyck, AIA. “Throughout the design process, we have been inspired by the convergences that this project represents. At the heart of it all is the convergence of UIC’s mission and the region’s growing tech prominence. For so many in the region, this new building will symbolize opportunity.” Creating a contemporary addition to this iconic brutalist campus, the building is functional, flexible, and respectful of the context. Located at a unique, prominent site on campus, the structure celebrates the natural setting and organic form of the Memorial Grove and establishes a new front door for technology in Chicago. Together with the existing lab building, the new CDRLC creates a dramatic public atrium for social interactions with visual and physical connections to all floors. The refined precast concrete and terra cotta façade of the building are inspired by Netsch’s late modern architecture and respond to the site conditions and the Memorial Grove. "The creation of the Computer Design, Research, and Learning Center at UIC is the type of investment Illinois needs to give our students a competitive advantage in the digital age. I'm fortunate to have an incredible research facility like UIC in my district, and I look forward to seeing the output of this building once complete," stated State Representative Lakesia Collins. "The announcement of the new Computer Design, Research, and Learning Center at UIC is crucial in order for the university to keep producing the incredible talent that it does. This state-of-the-art facility will further enhance the research taking place at UIC, while also welcoming prospective students to a unique learning environment," said State Senator Patricia Van Pelt. "I look forward to seeing this project completed in such an expedited timeframe, doubling the capacity of the Computer & Science Department in just two years," added Van Pelt. David Mann, Booth Hansen Principal, Comments: “The new building will be located adjacent to one of the original Netsch buildings, near other College of Engineering facilities and Memorial Grove. This unique site allows for an innovative design that is inspired by the context, materiality, and qualities of precast concrete material. The project breaks free from the rigid orthogonal character of the campus with a more organic connected form that reframes this edge of campus and the Grove.” Building on UIC’s successes with geo-thermal energy resources, the project will include a substantial new geo-thermal farm in the Memorial Grove, and the building has been designed to achieve LEED Gold certification. Reflecting a complex organization of requirements, the building will prompt students to cross paths with one another and enhance intellectual exchange. The atrium will be porous and dynamic with connections to the campus and the community, honoring the past and looking to the future. Booth Hansen has collaborated with many academic institutions in the Midwest over the last 40 years. Those colleges and universities include the University of Illinois Chicago, Northwestern University, University of Chicago, Columbia College, University of Illinois Urbana-Champaign, University of Wisconsin-Madison and the School of the Art Institute of Chicago. LMN Architects is a leader in the design of higher education facilities across the United States. Other completed projects include the Bill & Melinda Gates Center for Computer Science & Engineering at the University of Washington; the Voxman Music Building at the University of Iowa in Iowa City; the Anteater Learning Pavilion at the University of California, Irvine; and the Huntsman School of Business Addition at Utah State University in Logan, Utah. About LMN ArchitectsSince its founding in 1979, LMN Architects has dedicated its practice to the health and vitality of communities of all scales. Internationally recognized for the planning and design of environments that elevate the social experience. The firm works across a diversity of project typologies, including higher education facilities, science and technology, civic and cultural projects, conference and convention centers, urban mixed-use and transportation. LMN has successfully completed more than 700 projects across North America, such as the Voxman Music Building at the University of Iowa in Iowa City, Iowa; Tobin Center for the Performing Arts in San Antonio, Texas; Vancouver Convention Centre West in Vancouver, Canada; Seattle Academy of Arts and Sciences Middle School in Seattle, Washington; Bill & Melinda Gates Center for Computer Science and Engineering at the University of Washington in Seattle, Washington; Sound Transit University of Washington Station in Seattle, Washington; and the recently completed expansion and renovation of the Seattle Asian Art Museum. Based in Seattle, Washington, the firm employs 150 talented professionals practicing architecture, interior design, and urban design. The quality of the work has been recognized with nearly 300 national and international design awards, including the prestigious 2016 National Architecture Firm Award from the American Institute of Architects (AIA). For more information on the work of LMN Architects, please visit lmnarchitects.com Attachments CDRLC_01_Image Credit LMN Architects CDRLC_02_Image Credit LMN Architects CONTACT: Edgar Almaguer, Communications & Media Strategist LMN Architects 2066823460 ealmaguer@lmnarchitects.com
6 minutes ago
GlobeNewswire
EXL Recognized as a Visionary in Gartner Magic Quadrant for Data and Analytics Services 2021
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading operations management and analytics company, today announced its placement as a Visionary in the Gartner Magic Quadrant for Data and Analytics Services 2021. The report highlights several of EXL’s strengths, including its customizable analytics solutions combining domain expertise and data assets, partner-based models for co-developing innovative products with clients, and ability to create industry solutions with targeted value propositions. “In today's volatile and uncertain environment companies need to rely on data driven decisions to build and sustain market advantage. We at EXL are committed to help our clients leverage advanced analytics services including AI, machine learning, data scoring solutions, and cloud enablement to help them create market differentiation,” said Vivek Jetley, Executive Vice President and Head of Analytics, EXL. “I believe that being recognized as a Visionary, along with our distinction as the Gartner Peer Insights Customers’ Choice, demonstrates our strong data and analytics offerings, and we will continue to invest in these areas.” Said Anita Mahon, Executive Vice President and Chief Growth & Strategy Officer, EXL, “Our commitment to being an indispensable partner to data-led businesses sits at the heart of our analytics capabilities. I am pleased to see our data investments and strategy be recognized by this placement, and look forward to driving further growth and innovations in this area.” Additional strengths noted in the report included: Services and solutions benefiting from strong key domain expertise and data assets curated from industry sourcesJoint customer product R&D based on IP sharing, joint go-to-market strategies, and revenue sharing modelsAn acquisition strategy focusing on advanced analytics, AI, and data modernization fueled by the cloud This latest placement follows EXL receiving the Customer’s Choice distinction in the report Gartner Peer Insights ‘Voice of the Customer’: Data and Analytics Service Providers. EXL was the only company to receive this recognition based on receiving over 50 reviews from customers, with clients offering statements such as how “EXL are fantastic partners, bringing innovation and business savvy to our engagements in addition to the analytical horsepower they employ.” More information on this placement and the full report can be found by visiting this link. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About EXLEXL (NASDAQ: EXLS) is a leading operations management and analytics company that helps our clients build and grow sustainable businesses. By orchestrating our domain expertise, data, analytics and digital technology, we look deeper to design and manage agile, customer-centric operating models to improve global operations, drive profitability, enhance customer satisfaction, increase data-driven insights, and manage risk and compliance. Headquartered in New York, EXL has approximately 31,900 professionals in locations throughout the United States, the United Kingdom, Europe, India, the Philippines, Colombia, Canada, Australia and South Africa. EXL serves customers in multiple industries including insurance, healthcare, banking and financial services, utilities, travel, transportation and logistics, media and retail, among others. For more information, visit www.exlservice.com. CONTACT: Investor Relations Steven N. Barlow Vice President Investor Relations 212-624-5913 steven.barlow@exlservice.com Media - US Michael Sherrill Vice President Marketing 646-419-0778 michael.sherrill@exlservice.com Media - Europe, India and APAC Shailendra Singh Vice President Corporate Communications +91-98104-76075 shailendra.singh@exlservice.com
6 minutes ago
GlobeNewswire
Saatchi Art Presents the Launch of The Other Art Fair Virtual Editions, An Innovative New Virtual Reality Art Fair Series
In Partnership with BOMBAY SAPPHIRE®, the Global Launch of these VR Art Fairs Offers Guests Unique Programming, Live Experiences and Unparalleled Access to Top Emerging Artists SANTA MONICA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- The Other Art Fair, a leading artist fair for discovering emerging artists, will launch its new virtual reality art fair series with The Other Art Fair Global Virtual Editions on March 10-14. This debut Global Virtual Edition event will feature 75 of The Other Art Fair’s top emerging artists from around the globe within a three-dimensional virtual fair environment -- no headset required. The event will be supported by an immersive online program hosted on theotherartfair.com that will bring the unique experience of attending one of The Other Art Fair’s live events to life virtually for a global audience. “The Other Art Fair is known for creating a highly experiential program for fairgoers, while providing them access to exciting new emerging artists,” said Ryan Stanier, founder of The Other Art Fair. “Our new Virtual Edition fairs beautifully adapt that in-real-life experience to our innovative virtual platform, offering participants the chance to explore artist booths, participate in live fair tours, workshops and lectures, and gain direct access to the exhibiting artists, all from the comfort of their computer or phone.” The Global Virtual Edition kicks off the worldwide 2021 virtual fair tour for The Other Art Fair, which will include dedicated virtual events for all Fair exhibitions, including events in Los Angeles, London, Sydney, Brooklyn, Chicago, Dallas, and Toronto. Each Virtual Edition event will also feature workshops and VR programming unique to that city, creating a special experience that celebrates each market and its local art community. A signature element to every The Other Art Fair event is the direct connection attendees have to exhibiting artists. The Virtual Edition allows fairgoers to schedule a live chat with an exhibiting artist for a one-on-one discussion about the artist’s process, key artworks for sale and a chance to learn more about the artist’s background. Added Sean Moriarty, CEO of Leaf Group, “at Leaf Group, we are constantly striving to create the best experience possible for our audiences, and we are excited for the launch of The Other Art Fair’s first virtual reality fair. This innovative program further strengthens our mission of supporting artists worldwide through a virtual reality platform that connects them with a global art collector audience.” The Other Art Fair Global Virtual Edition runs from March 10-14, with Artist Room Preview Days on March 10, 11, 12. The event will showcase 75 of the top emerging artists, supported by a program of interactive virtual content. Some highlights from the Global Virtual Edition programming include: Chat With An Artist: Opportunities to meet and talk to the talented exhibiting artists about their work, inspiration and process, or to see an artwork in more detail and ask questions about a specific piece.Virtual Editions Live Talks, Workshops and Tours: Explore the artist’s studios through engaging talks and tours that uncover the creative process behind many of the works on display at the Virtual Edition. All free to register, talks and tours will include: º Bombay & Tonic Customization with Valentino Longo: The Other Art Fair has partnered with BOMBAY SAPPHIRE® to create a virtual workshop for guests to learn about the BOMBAY & Tonic, why the two pair together so well, and how to make three upgraded versions at home. Guests must be of legal drinking age to view and share this workshop. º Invest in Art with Rebecca Wilson: Join Saatchi Art’s Chief Curator Rebecca Wilson as she shares what to look for when investing in emerging artists. º Artistic Process: For many artists, the process is just as important as the finished product. Saatchi Art Curator Megan Wright introduces the makers of some of the fair’s most popular artworks to gain insights into their creation. º Live Fair Tours of Artist Rooms 1, 2, and 3: LA and Dallas Fair Director Nicole Garton introduces her top artists from Artist Room 1; London Fair Manager Anouka Pedley introduces her top artists from Artist Room 2; East Coast Fair Assistant Sasha Ali introduces her top artists from Artist Room 3. Build Your Own Happy Character - An Interactive Experience by Eva Cremers: Through an interactive experience, visitors can tap into their own cheeky, creative side with an interactive, drag-and-drop tool that allows you to create your own Happy Character.Gommie Live Poetry Reading: Artist and poet Gommie will perform live and showcase some of his artwork.Girls in Film Short Film Screenings: Girls in Film represents, champions and connects the new generation of female-identified creatives in the film industry. The organization has curated a selection of five short films for The Other Art Fair to showcase rising filmmakers from London, South Africa, Prague and Amsterdam. ARTIST ROOMS The featured artists will be showcased across three rooms to allow the visitor to more easily digest all artist stands. Each Artist Room will also contain exclusive experiential content and have its own dedicated Preview day, providing a first look at that Artist Room’s exhibitors while the other rooms are closed. Visitors are encouraged to pre-register, for free access to these Previews. All rooms will be carefully curated by the fair team to ensure an exciting and varied breadth of medium. Visitors can also take a pre-recorded ‘Room Highlights' tour by the Fair Director before they enter. ROOM 1 | Preview on Wednesday, March 10Discover bright colors, fun sculptural works, inspirational portraits, plus much more ROOM 2 | Preview on Thursday, March 11Get lost in large-scale abstracts, thoughtful photography, poetry, street art, plus more ROOM 3 | Preview opens on Friday, March 12 Be swept away by some beautiful paintings, enchanting illustrations, photography, and more To learn more about The Other Art Fair Global Virtual Edition, visit https://www.theotherartfair.com/. About The Other Art FairThe Other Art Fair, a leading artist fair for discovering emerging artists, provides a platform for artists to present and sell their work directly to art buyers both through in-person events and online. Each fair presents more than 90 artists chosen by a selection committee of art experts, enabling both collectors and first-time buyers to buy directly from emerging artists. Since 2011, The Other Art Fair has worked with over 3,000 artists from more than 20 countries, with fairs based in the UK, US and Australia. Unlike “other” fairs, The Other Art Fair creates an accessible and open fair designed for visitors to enjoy an interactive and immersive experience. www.theotherartfair.com About Saatchi ArtLeading online art gallery Saatchi Art features one of the world’s largest selections of original art and helps people all over the world find art and artists they love. The online art gallery offers original paintings, drawings, sculptures and photographs by over 100,000 emerging artists from over 100 countries. Saatchi Art is redefining the experience of buying and selling art by providing art lovers with free art advisory services and an expertly curated selection of art, while giving artists a convenient and welcoming environment in which to exhibit and sell their work. To discover the world of Saatchi Art, please visit www.saatchiart.com. Saatchi Online, Inc., which operates Saatchi Art, is a wholly owned subsidiary of Leaf Group Ltd. (NYSE: LEAF). About Leaf GroupLeaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness & wellness (Well+Good, Livestrong.com and MyPlate App), and home, art & design (Saatchi Art, Society6 and Hunker). For more information about Leaf Group, visit www.leafgroup.com. Media Contact:Sharna DadukVP, Communicationssharna.daduk@leafgroup.com Mia MendezDirector, Public Relationsmia.mendez@leafgroup.com
6 minutes ago
GlobeNewswire
Veru Exploring Strategic Alternatives for its Legacy Female Health Business
MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® / FC2 Internal Condom business (FHC Business). “With the last two consecutive quarters for our FHC Business having set all-time historical records in terms of net revenues and gross profit, and with the last three-year compound annual growth rates for the FHC Business’ net revenues and gross profit being 60% and 83%, respectively, we think this is an ideal time to consider strategic alternatives, including the possibility of monetizing this business, as we recently did with our PREBOOST business,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer. “Furthermore, with the potential for five registration clinical trials in calendar year 2021 -- four for oncology indications and one for COVID-19 — it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was.” Dr. Steiner added: “The FHC Business has been a great business for Veru. Fiscal year 2020 was a record year in terms of net revenues of $41 million and gross profit of $29 million, and Q1 fiscal year 2021 is already off on another record-setting pace. The cash flow generated by the FHC Business has allowed Veru to significantly advance its biopharmaceutical clinical programs. We are open to exploring the right kind of strategic transaction for the FHC Business with a view towards the best, long-term interests of Veru shareholders, which may include continuing to operate the FHC Business if we ultimately decide that is in our shareholders’ best interests.” About the FHC BusinessThe FHC Business is Veru’s legacy business. Its commercial product is the FC2 Female Condom®/ FC2 Internal Condom (“FC2”), the only FDA approved female condom that provides dual protection against unintended pregnancy and the transmission of sexually transmitted infections. FC2 is sold commercially and in the public health sector both in the U.S. and globally. In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies. In the global public health sector, the Company markets FC2 to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. Over 650 million FC2 units have been sold globally in 159 countries. The FHC Business record growth has demonstrated a resiliency to the impact of the COVID-19 pandemic through a proven telemedicine prescription sales model. To learn more about the FC2 product, please visit www.verupharma.com "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: There can be no assurance that any FHC Business strategic transaction will occur and there is no definitive timetable for such. The Company does not intend to make future announcements concerning this matter, unless or until it enters into a definitive agreement, or its board of directors determines to conclude the process, or it otherwise deems that further disclosure is appropriate or required. The statements in this release that are not historical facts are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding strategic alternatives with respect to, and the Company's ability to potentially monetize the Company's legacy FHC Business, and the anticipated timeframe for clinical studies and FDA submissions of the Company’s biopharmaceutical drug candidates. Any forward-looking statements in this release are based upon the Company's current plans and strategies and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: the risk that the Company may not enter into a definitive agreement or otherwise proceed with any transaction regarding its FHC Business; costs, fees and expenses related to the process of exploring strategic alternatives with respect to the FHC Business and the risk that the process may divert management’s attention from managing our business operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies due to COVID-19, and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of any submission to the FDA and regulatory approval of products under development and the risk that disruptions at the FDA caused by the COVID-19 pandemic may delay the review of submissions or approvals for new drugs; the risk of a delay or failure in reaching agreement with the FDA on the design of a clinical trial or in obtaining authorization to commence a clinical trial; preclinical or clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified product candidate or at all; our pursuit of a COVID-19 treatment candidate is at an early stage and we may be unable to develop a drug that successfully treats the virus in a timely manner, if at all; risks related to our commitment of financial resources and personnel to the development of a COVID-19 treatment which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties about the longevity and extent of COVID-19 as a global health concern and the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated; government entities may take actions that directly or indirectly have the effect of limiting opportunities for VERU-111 as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the risk that the Company's products may not be commercially successful; risks related to the impact of the COVID-19 pandemic on our business, the nature and extent of which is highly uncertain and unpredictable; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations, including our ability to secure timely grant or other funding to develop VERU-111 as a potential COVID-19 treatment; product demand and market acceptance; competition in the Company's markets and therapeutic areas and the risk of new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; the risk that the Company will be affected by regulatory developments, including a reclassification of products; price erosion, both from competing products and increased government pricing pressures; manufacturing and quality control problems; compliance and regulatory matters, including costs and delays resulting from extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in reimbursement and coverage or reclassification of products; some of the Company's products are in development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including the uncertainty of obtaining patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; the risk that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company's reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; risks related to the costs and other effects of litigation, including product liability claims; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2020 and subsequent quarterly reports on Form 10-Q. These documents are available on the "SEC Filings" section of our website at www.verupharma.com/investors. Investor Contact:Sam Fisch veruinvestor@verupharma.comDirector of Investor Relations Corporate Development Contact:Kevin Gilbert kgilbert@verupharma.comEVP Corporate Development
6 minutes ago
GlobeNewswire
Bubblr Engages PubCo Reporting Solutions to Elevate Reporting Status on Path to Uplisting
LONDON, UK, March 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Bubblr, Inc. (OTC PINK: BBLR) ("Bubblr" or the "Company"), an ethical technology company focused on the development and commercialization of mobile-first technologies, today announced that it has engaged the services of PubCo Reporting Solutions, Inc. PubCo Reporting Solutions specializes in Outsourced CFO, financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulatory compliance solutions for public companies. PubCo partners with management teams offering internal control assessment and implementation services as well as assisting them with complex financial reporting requirements. Steven Saunders, Chief Executive Officer of Bubblr, commented, "Among our goals since becoming a public company in August 2020 is the completion of an initial independent audit, which is the first step to become a fully SEC reporting company. Pubco Reporting Solutions will assist us in the preparation of financial statements that we plan to have audited by a PCOAB auditor prior to reporting with the SEC. We believe this is the path that best supports our goals for an upgrade to the OTCQB quotation tier and eventually to listing with a national exchange. We are resolute in our intention to follow this roadmap and accomplish that goal. PubCo Reporting has extensive experience in assisting public companies in realizing these important objectives, and we welcome them to the Bubblr team.” About Bubblr, Inc. Bubblr, Inc. is an ethical technology company focused on mobile-first technology that aims to bring back privacy to users, trust in online content, and sustainability to the digital marketplace. Through its portfolio of digital mobile apps, Bubblr's next-generation mobile ecosystem, and platform, partners with publishers to address challenges related to free online content, while protecting end-users from data harvesting and manipulation. These ecosystems connect into a new model for online search, which is a fair and sustainable ad-free marketplace. For more information, visit http://www.bubblr.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words' estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks. Contact:Investor RelationsStephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com
6 minutes ago
Business Wire
FIDO Alliance Announces First 2021 Authenticate Virtual Summit, focusing on Modern Authentication for Financial Services
The FIDO Alliance Authenticate conference announced speakers for the 2021 Virtual Summit: "Modern Authentication for Financial Services" on March 25.
6 minutes ago
GlobeNewswire
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III
NOVATO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX053, an investigational mRNA therapy being evaluated for the treatment of Glycogen Storage Disease Type III (GSDIII). Enrollment in a Phase 1/2 study is expected to begin in the second half of 2021. “FDA IND clearance paves the way for UX053 to enter the clinic as the first possible pharmacologic treatment option for patients with GSDIII,” said Camille L. Bedrosian, M.D., Chief Medical Officer of Ultragenyx. “UX053 is the most advanced of our investigational mRNA therapies, with multiple others in earlier preclinical development, and will be one of the first mRNA programs to enter clinical development for rare genetic diseases.” Ultragenyx is developing UX053 and a number of other mRNA therapies in the preclinical stage for undisclosed indications. These mRNA therapies come out of a long-term collaboration with Arcturus Therapeutics, a clinical-stage messenger RNA medicines company. Study Design The two-part Phase 1/2 clinical trial will evaluate the safety, tolerability, and efficacy of UX053 in adults with GSDIII. Part 1 is open label and will enroll up to 12 patients who receive a single ascending dose of UX053. Part 2 is a randomized, double-blind, placebo-controlled multi-ascending study of 5 doses. It will enroll up to 16 patients across four cohorts randomized 3:1 to UX053 or placebo. In addition to safety, tolerability, and pharmacokinetics, study endpoints include clinician- and patient-reported outcomes, muscle strength, and biomarkers of liver, cardiac, and muscle health. About Glycogen Storage Disease Type III Our preclinical candidate UX053 is being developed for the treatment of GSDIII, a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. GSDIII can cause hepatomegaly, hypoglycemia, hyperlipidemia, some progressive liver cirrhosis, and skeletal and cardiac muscle disease. There are no approved treatment options for GSDIII and the current standard of care is a strict diet, including frequent doses of cornstarch, to reduce the risk of hypoglycemia. GSDIII affects more than 10,000 patients in the developed world. About UX053 UX053 is an investigational mRNA-based biologic therapy encoding full-length, glycogen debranching enzyme encapsulated in a lipid nanoparticle (LNP) designed to provide the deficient protein in GSDIII. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx's expectations and projections regarding its future operating results and financial performance, anticipated cost or expense reductions, the timing, progress and plans for its clinical programs and clinical studies, future regulatory interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the effects from the COVID-19 pandemic on the company’s clinical activities, business and operating results, risks related to reliance on third party partners to conduct certain activities on the company’s behalf, uncertainty and potential delays related to clinical drug development, smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2021, and its subsequent periodic reports filed with the Securities and Exchange Commission. Contact Ultragenyx Pharmaceutical Inc.Investors & MediaJoshua Higa415-660-0951
6 minutes ago

ALL ORDS

AUD/USD

ASX 200

OIL

GOLD

BTC-AUD

CMC Crypto 200

YOU'RE INVITED: Breakfast and investing tips

COVID-19 Impacts and Recovery | Global Fire Detection And Suppression Systems Market Research during 2020-2024 | Technavio

Latest stories

Frontdoor to Participate at the Truist Securities Technology, Internet & Services Conference

Explainer: Why protests are shaking one of Africa's most stable democracies

What Stock Market Sell-Off? These Stocks Are Red Hot

Glenfarne Group and Partners Group Announce EnfraGen’s Expanded Presence in Colombia Through Termovalle Acquisition

Global Greeting Cards Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com

Saudi wealth fund PIF to support corporate credit growth, S&P says

Consolidated Water to Participate at the Virtual 33rd Annual ROTH Conference on March 15-17, 2021

OSS to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

Keith Cochran Joins KULR Technology Group as President & COO

Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management System

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Danimer Scientific Announces Date for Fourth Quarter and Full Year 2020 Results

Fieldpoint Private Surpasses Two Major Milestones

LMN Architects and Booth Hansen Celebrate the Design and Construction of the New Computer Design, Research, and Learning Center at the University of Illinois Chicago

EXL Recognized as a Visionary in Gartner Magic Quadrant for Data and Analytics Services 2021

Saatchi Art Presents the Launch of The Other Art Fair Virtual Editions, An Innovative New Virtual Reality Art Fair Series

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

Bubblr Engages PubCo Reporting Solutions to Elevate Reporting Status on Path to Uplisting

FIDO Alliance Announces First 2021 Authenticate Virtual Summit, focusing on Modern Authentication for Financial Services

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III